norfluoxetine has been researched along with dextromethorphan in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 3 (60.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
Cheung, SW; Joffe, RT; Otton, SV; Sellers, EM; Wu, D | 1 |
Albano, D; Amchin, J; Ereshefsky, L; Klockowski, PM; Taylor, K; Zarycranski, W | 1 |
Guo, B; He, MM; Li, C; Liu, H; Shen, H; Wang, L; Wrighton, SA | 1 |
Davis, C; Foti, RS; Isoherranen, N; Kunze, KL; Lutz, JD; Sager, JE | 1 |
1 trial(s) available for norfluoxetine and dextromethorphan
Article | Year |
---|---|
Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe.
Topics: Administration, Oral; Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Cytochrome P-450 CYP2D6; Dextromethorphan; Dextrorphan; Drug Interactions; Female; Fluoxetine; Humans; Male; Metabolic Clearance Rate; Phenotype; Selective Serotonin Reuptake Inhibitors; Time Factors; Urinalysis; Venlafaxine Hydrochloride | 2001 |
4 other study(ies) available for norfluoxetine and dextromethorphan
Article | Year |
---|---|
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Inhibition by fluoxetine of cytochrome P450 2D6 activity.
Topics: Adult; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Fluoxetine; Humans; In Vitro Techniques; Male; Microsomes, Liver; Middle Aged; Mixed Function Oxygenases; Multiple Sclerosis; Oxidation-Reduction; Oxycodone; Phenotype; Selective Serotonin Reuptake Inhibitors | 1993 |
Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.
Topics: Atomoxetine Hydrochloride; Cocaine; Codeine; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Dextromethorphan; Enzyme Inhibitors; Ethanolamines; Fluoxetine; Humans; Hydroxylation; Imipramine; Kinetics; Microsomes; Molecular Structure; Nortriptyline; Polymorphism, Single Nucleotide; Propylamines; Quinidine; Recombinant Proteins; Thioridazine; Tramadol | 2007 |
Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4.
Topics: Adult; Antidepressive Agents, Second-Generation; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biotransformation; Computer Simulation; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dextromethorphan; Drug Interactions; Female; Fluoxetine; Half-Life; Hepatocytes; Humans; Lovastatin; Male; Midazolam; Models, Statistical; Omeprazole; Stereoisomerism | 2014 |